Overview
- The Phase 3 TALAPRO-3 trial met its primary endpoint, showing a statistically significant and clinically meaningful rPFS improvement versus enzalutamide alone in HRR‑mutated metastatic castration‑sensitive prostate cancer.
- Topline results exceeded the prespecified hazard‑ratio target of 0.63, with most patients remaining progression‑free at the time of analysis.
- Efficacy was consistent across tumors with BRCA and non‑BRCA HRR gene alterations, with an interim trend toward improved overall survival and advantages on key secondary measures.
- The safety profile of the combination aligned with the known profiles of each drug, and no new safety signals were reported.
- Pfizer will submit the data for presentation and discuss potential filings with global regulators, building on existing approvals for the combo in mCRPC; separately, a Phase 2 breast cancer study also met its PFS goal.